X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (84) 84
hematology (54) 54
female (37) 37
male (36) 36
peripheral vascular disease (35) 35
index medicus (33) 33
aged (26) 26
middle aged (26) 26
adult (23) 23
anticoagulants (21) 21
venous thromboembolism (21) 21
rivaroxaban (20) 20
anticoagulants - therapeutic use (18) 18
factor xa inhibitors (18) 18
thrombosis (18) 18
risk factors (16) 16
prevention (15) 15
deep-vein thrombosis (13) 13
animals (12) 12
anticoagulants - administration & dosage (12) 12
heparin (12) 12
molecular-weight heparin (12) 12
thromboembolism (12) 12
administration, oral (11) 11
anticoagulants - pharmacology (11) 11
blood coagulation - drug effects (11) 11
enoxaparin (11) 11
thromboembolism - prevention & control (11) 11
anticoagulants - adverse effects (10) 10
coagulation (10) 10
hematology, oncology and palliative medicine (10) 10
life sciences (10) 10
dose-response relationship, drug (9) 9
double-blind method (9) 9
fibrinolytic agents - therapeutic use (9) 9
hemorrhage - chemically induced (9) 9
pregnancy (9) 9
treatment outcome (9) 9
unfractionated heparin (9) 9
venous thrombosis (9) 9
aged, 80 and over (8) 8
dabigatran (8) 8
drug therapy (8) 8
medicine, general & internal (8) 8
plasma (8) 8
prothrombin time (8) 8
thrombophilia (8) 8
apixaban (7) 7
drug monitoring - methods (7) 7
heparin - therapeutic use (7) 7
in-vitro (7) 7
medicine & public health (7) 7
pharmacodynamics (7) 7
pharmacokinetics (7) 7
prophylaxis (7) 7
therapy (7) 7
thrombin (7) 7
thrombosis - prevention & control (7) 7
analysis (6) 6
beer (6) 6
biochemistry (6) 6
blood (6) 6
chemistry (6) 6
compositions or test papers therefor (6) 6
condition-responsive control in microbiological orenzymological processes (6) 6
enzymes (6) 6
enzymology (6) 6
factor xa inhibitor (6) 6
heparin, low-molecular-weight - therapeutic use (6) 6
human necessities (6) 6
hygiene (6) 6
investigating or analysing materials by determining theirchemical or physical properties (6) 6
measuring (6) 6
measuring or testing processes involving enzymes, nucleicacids or microorganisms (6) 6
medical or veterinary science (6) 6
metallurgy (6) 6
microbiology (6) 6
morpholines - blood (6) 6
morpholines - pharmacology (6) 6
mutation (6) 6
mutation or genetic engineering (6) 6
physics (6) 6
preparations for medical, dental, or toilet purposes (6) 6
processes of preparing such compositions (6) 6
pulmonary embolism (6) 6
pulmonary-embolism (6) 6
spirits (6) 6
testing (6) 6
thiophenes - blood (6) 6
thiophenes - pharmacology (6) 6
thromboprophylaxis (6) 6
time factors (6) 6
venous thrombosis - prevention & control (6) 6
vinegar (6) 6
wine (6) 6
abridged index medicus (5) 5
adolescent (5) 5
antithrombin-iii (5) 5
blood coagulation tests (5) 5
blood coagulation tests - standards (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2000, ISBN 185317775X, viii, 270
Book
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 2868 - 2868
Abstract Specific anti-activated factor X molecules are currently used for the prevention and the treatment of various thromboembolic disorders. However,... 
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Drug Development Research, ISSN 0272-4391, 12/2013, Volume 74, Issue 8, pp. 582 - 586
Journal Article
La Presse Medicale, ISSN 0755-4982, 06/2012, Volume 41, Issue 6, pp. 557 - 559
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 10/2007, Volume 98, Issue 4, pp. 756 - 764
Venous thromboembolism (VTE) is often asymptomatic, mis-diagnosed, and unrecognized at death, and there is a lack of routine postmortem examinations. These... 
Deep-vein thrombosis | pulmonary embolism | VTE prophylaxis | venous thromboembolism | post-thrombotic syndrome | pulmonary hypertension | Pulmonary embolism | Pulmonary hypertension | Venous thromboembolism | Post-thrombotic syndrome | COST-EFFECTIVENESS ANALYSIS | RISK-FACTORS | LONG-TERM COMPLICATIONS | FOLLOW-UP | POSTTHROMBOTIC SYNDROME | MOLECULAR-WEIGHT HEPARIN | PULMONARY-EMBOLISM | deep-vein thrombosis | MAJOR ORTHOPEDIC-SURGERY | MEDICAL PATIENTS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Hypertension, Pulmonary - mortality | Venous Thromboembolism - mortality | Europe | Humans | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Male | Risk | Hypertension, Pulmonary - epidemiology | Pulmonary Embolism - epidemiology | Morbidity | Pulmonary Embolism - mortality | Postthrombotic Syndrome - epidemiology | Postthrombotic Syndrome - mortality | Algorithms | Hospitals | Venous Thrombosis - epidemiology | Female | Registries | Venous Thromboembolism - epidemiology | Anticoagulants | Venous Thrombosis | Hypertension, Pulmonary | Postthrombotic Syndrome | Life Sciences | Human health and pathology | Venous Thromboembolism | Pulmonary Embolism | Medical and Health Sciences | Medicin och hälsovetenskap | Respiratory disease | Mortality | Post-thrombotic disease | Deep vein thrombosis | Cardiovascular disease | MEDICINE | Venous disease | Vascular disease | Prevention | MEDICIN | Venous thrombosis | Thromboembolism
Journal Article
Journal Article
Presse Medicale, ISSN 0755-4982, 2012, Volume 41, Issue 6, pp. 557 - 559
Journal Article
Drugs & Aging, ISSN 1170-229X, 3/2011, Volume 28, Issue 3, pp. 177 - 193
Elderly people with renal impairment are at high risk for venous thromboembolism (VTE) and acute coronary syndromes (ACS); however, they are also at increased... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | Research-and-development | Fondaparinux-sodium, therapeutic use | Rivaroxaban, therapeutic use | Dabigatran-etexilate, therapeutic use | Low-molecular-weight-heparins, therapeutic use | Venous-thromboembolism, prevention | Dalteparin-sodium, therapeutic use | Renal-impairment | Deep-vein-thrombosis, prevention | Anticoagulants, therapeutic use | Elderly | Enoxaparin-sodium, therapeutic use | GLOMERULAR-FILTRATION-RATE | WAVE MYOCARDIAL-INFARCTION | COCKCROFT-GAULT FORMULA | DEEP-VEIN THROMBOSIS | PHARMACOLOGY & PHARMACY | ACUTE CORONARY SYNDROMES | VS. UNFRACTIONATED HEPARIN | PLACEBO-CONTROLLED TRIAL | THROMBIN INHIBITOR DABIGATRAN | FACTOR XA INHIBITOR | ILL MEDICAL PATIENTS | GERIATRICS & GERONTOLOGY | Kidney - drug effects | Anticoagulants - metabolism | Humans | Heparin, Low-Molecular-Weight - adverse effects | Anticoagulants - adverse effects | Kidney - metabolism | Venous Thromboembolism - complications | Venous Thromboembolism - chemically induced | Heparin, Low-Molecular-Weight - metabolism | Aged | Kidney Diseases - complications | Kidney - physiopathology | Kidney Diseases - metabolism | Platelet Aggregation Inhibitors - adverse effects | Prevention | Complications and side effects | Care and treatment | Anticoagulants (Medicine) | Dosage and administration | Kidney diseases | Thromboembolism | Drug therapy | Risk factors
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 8, pp. 699 - 708
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 02/2012, Volume 107, Issue 2, pp. 379 - 387
Journal Article